Content about Due diligence

September 17, 2012
ProPhase rejects Matrixx acquisition proposal

ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.

DOYLESTOWN, Pa. — ProPhase Labs on Monday announced that it rejected an unsolicited, nonbinding proposal from Matrixx Initiatives to acquire the company for $1.40 per share in cash, subject to further due diligence by Matrixx.

ProPhase stock was up 20 cents to $1.39 in mid-afternoon trading.

Matrixx is the owner of the Zicam brand of cold and allergy products and is a direct competitor to ProPhase's Cold-Eeze Cold Remedy product line.

September 6, 2012
Physicians Formula receives acquisition proposal

Beauty brand Physicians Formula Holdings has received an unsolicited, nonbinding proposal to acquire all its outstanding shares of common stock at a price of $4.90 per share.

AZUSA, Calif. — Beauty brand Physicians Formula Holdings has received an unsolicited, nonbinding proposal to acquire all its outstanding shares of common stock at a price of $4.90 per share.

The proposal is subject to several conditions, including the completion of due diligence and securing of financing commitments by the third party who submitted the proposal and the negotiation of a mutually acceptable definitive agreement.

November 21, 2011
Perrigo names M&A vet to corporate development post

Perrigo on Monday named Christopher Roop to the post of VP corporate development.

ALLEGAN, Mich. — Perrigo on Monday named Christopher Roop to the post of VP corporate development. In this role, Roop will be responsible for identifying, evaluating and pursuing acquisition targets that complement the company’s strategic growth objectives.

July 15, 2011
Clorox receives acquisition proposal from Icahn Enterprises

Clorox on Friday confirmed it has received an unsolicited conditional proposal from Icahn Enterprises to acquire the company for $76.50 per share, subject to due diligence, financing and other conditions.

OAKLAND, Calif. — Clorox on Friday confirmed it has received an unsolicited conditional proposal from Icahn Enterprises to acquire the company for $76.50 per share, subject to due diligence, financing and other conditions. Clorox said its board of directors, in consultation with its financial and legal advisers, will review the proposal in due course. 

Goldman, Sachs & Co. and J.P. Morgan Securities are serving as financial advisers, and Wachtell, Lipton, Rosen & Katz is legal adviser.